Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

318
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
318
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Inhaled Medications01:23

Inhaled Medications

323
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
323
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

506
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
506
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

462
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
462
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

358
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
358

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A University Student-Led Hope-Based Intervention Improves Fruit and Vegetable Intake, Functional Fitness, and BMI Among Older Adults in Urban Alaska.

Journal of cross-cultural gerontology·2026
Same author

Combined indwelling pleural catheter with thoracoscopic talc poudrage for malignant pleural effusion management: a randomized non-inferiority trial.

BMC pulmonary medicine·2026
Same author

Recruitment strategies for lung cancer screening; a randomised trial in the 4-IN-THE-LUNG-RUN study.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

WABIP/AABIP statement on therapeutic indications of medical thoracoscopy for benign pleural disease.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Evaluation of the SEPAR-ALAT Asthma Exacerbation Severity Classification.

Archivos de bronconeumologia·2026
Same author

Effectiveness of FF/UMEC/VI versus ICS/LABA in Patients with Uncontrolled Asthma Treated in Routine Clinical Practice (PERFORM): A Pragmatic Randomized Controlled Trial.

Journal of asthma and allergy·2026

Related Experiment Video

Updated: Jul 27, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

SABAs as Reliever Medications in Asthma Management: Evidence-Based Science.

Israel Amirav1, Gabriel Garcia2, Bao Khac Le3

  • 1Pediatric Pulmonology Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. amirav@ualberta.ca.

Advances in Therapy
|June 6, 2023
PubMed
Summary
This summary is machine-generated.

Short-acting beta-agonists (SABAs) as needed for asthma relief are safe and effective when used with inhaled corticosteroid (ICS) maintenance therapy. Increased SABA use indicates worsening asthma control and requires reassessment of ICS therapy.

Keywords:
As-needed relieverAsthma managementSABAScientific evidenceShort-acting β2-agonists

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.8K

Related Experiment Videos

Last Updated: Jul 27, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.8K

Area of Science:

  • Respiratory Medicine
  • Pharmacology

Background:

  • The use of short-acting beta-agonists (SABAs) as reliever medication in asthma management is debated.
  • Concerns exist regarding potential adverse effects and overuse of SABAs.

Purpose of the Study:

  • To review the current role of SABAs as reliever medications in asthma.
  • To examine challenges to appropriate SABA use and critique data leading to its condemnation.
  • To provide evidence and practical solutions for appropriate SABA use.

Main Methods:

  • Literature review and critical analysis of existing data on SABA use in asthma.
  • Examination of evidence supporting SABA as a reliever in conjunction with controller therapies.
  • Identification of strategies for managing SABA misuse, inhaler technique, and adherence.

Main Results:

  • No scientific evidence links SABA use as a reliever to increased mortality or serious adverse events when used with ICS.
  • Increased SABA consumption is a marker for poor asthma control and potential underuse of ICS.
  • Identifying patients at risk for SABA misuse is crucial for optimizing asthma management.

Conclusions:

  • Inhaled corticosteroid (ICS)-based maintenance therapy with as-needed SABA is an effective and safe asthma treatment.
  • Appropriate use of ICS controller therapy and SABA relievers should be promoted through education.
  • Early identification and intervention for patients misusing inhalers are essential for improved asthma control.